Oppenheimer Asset Management Inc. Lowers Stake in Veeva Systems Inc. $VEEV

Oppenheimer Asset Management Inc. decreased its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 3.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,439 shares of the technology company’s stock after selling 2,217 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Veeva Systems were worth $20,573,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of VEEV. Nuveen LLC acquired a new position in Veeva Systems during the 1st quarter worth about $365,684,000. Price T Rowe Associates Inc. MD increased its stake in Veeva Systems by 20.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock worth $924,754,000 after buying an additional 689,700 shares during the period. Linonia Partnership LP increased its stake in Veeva Systems by 52.7% during the 1st quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock worth $425,402,000 after buying an additional 633,585 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Veeva Systems by 48.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock worth $416,918,000 after buying an additional 585,785 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Veeva Systems by 10.7% during the 1st quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock worth $1,273,884,000 after buying an additional 532,269 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Analyst Ratings Changes

VEEV has been the topic of several recent research reports. Piper Sandler upped their target price on shares of Veeva Systems from $325.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. UBS Group boosted their target price on Veeva Systems from $285.00 to $310.00 and gave the stock a “neutral” rating in a research note on Thursday, August 28th. Citigroup lifted their price target on shares of Veeva Systems from $329.00 to $349.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Barclays lifted their price target on shares of Veeva Systems from $300.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. Finally, Morgan Stanley lifted their price target on shares of Veeva Systems from $210.00 to $222.00 and gave the stock an “underweight” rating in a research note on Thursday, August 28th. Seventeen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Veeva Systems has an average rating of “Moderate Buy” and a consensus target price of $307.58.

Insider Buying and Selling at Veeva Systems

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the transaction, the insider directly owned 25,325 shares in the company, valued at approximately $7,765,151.50. This trade represents a 19.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jonathan Faddis sold 14,595 shares of Veeva Systems stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.00, for a total value of $4,378,500.00. Following the completion of the transaction, the senior vice president owned 8,588 shares in the company, valued at $2,576,400. This trade represents a 62.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is owned by company insiders.

Veeva Systems Price Performance

NYSE VEEV opened at $293.11 on Friday. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The company has a market capitalization of $48.04 billion, a PE ratio of 60.19, a P/E/G ratio of 2.27 and a beta of 0.98. The company has a fifty day moving average of $284.70 and a two-hundred day moving average of $269.66.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The firm had revenue of $789.08 million during the quarter, compared to analysts’ expectations of $768.49 million. During the same quarter in the prior year, the firm posted $1.62 EPS. Veeva Systems’s quarterly revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, research analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.